AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Instrumental-assisted soft tissue mobilization (IASTM)
Description: Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental-assisted soft tissue mobilization (IASTM)
Description: Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Investigational Drug
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as comparator
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy (concomitant therapy)
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy (concomitant therapy)
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy (concomitant therapy)
Study NCT01544179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy (concomitant therapy)
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Load Strength Training
Description: Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Load Strength Training
Description: Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plantar Flexor and Gastrocnemius Stretching
Description: For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
Study NCT04162262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar Flexor and Gastrocnemius Stretching
Description: For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low dose
Description: This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl cysteine, 600mg (low dose)
Description: The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proimmune 200 (FT061452) 3000mg low dose
Description: The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
Study NCT02601638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling session with speech pathologist
Study NCT02601638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Laryngectomy Preoperative Education Class
Study NCT02601638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day of Hospital Discharge Laryngectomy Survey
Study NCT02601638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day of Discharge Practicum
Study NCT02601638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngectomy Education Study Exit Survey
Study NCT04654221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
Study NCT04621240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online SMART & Stress Solutions
Description: 1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
Study NCT01892150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Apply sunscreen before and after UVA and UVB irradiation
Study NCT03512808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol 500 MG
Description: Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
Study NCT03512808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte 500Mg Tablet
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Study NCT03533959 — intervention group
Intervention type: DRUG
Intervention: Alirocumab
Description: the administration of Alirocumab at least 75mg every 2 weeks
Study NCT02142400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093
Description: DS-1093 in capsules with 2.5mg or 25mg per capsule
Study NCT02142400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsules to DS-1093 capsules
Study NCT04165382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interventions in the guideline to infants receiving NIV
Description: Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV
Study NCT04165382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care to infants receiving NIV
Description: Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
Study NCT00830375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10-30mg, by mouth, daily
Study NCT00493415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerin iv
Description: loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
Study NCT00493415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo = nacl 0.9%
Description: 4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
Study NCT03147755 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00752232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
Study NCT03307629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 delivered as rectal suppository.
Study NCT03307629 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation Therapy
Description: Radiation per selected tumour lesion.
Study NCT03155945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab active treatment for 8 weeks.
Study NCT01963143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex (5%)
Study NCT00752232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
Study NCT00752232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
Study NCT01963143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex 10
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (high dose)
Description: The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Study NCT00752232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: IM injection, Day 1, month 3, 6, 9, 12
Study NCT04502589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel Tablet
Description: Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
Study NCT00315237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine and best supportive care
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
Study NCT01844232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
Study NCT03850548 — intervention group
Intervention type: OTHER
Intervention: Prosthetic joint infection with Cutibacterium acnes
Description: patients having a prosthesis infection with C.acnes identified by specific PCR
Study NCT00530218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
Study NCT01160003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
Study NCT01160003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
Study NCT03759119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tummy time and parent education
Description: Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
Study NCT03759119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education only
Description: Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application.
Study NCT03388489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Walking
Description: walking, breathing, and mindfulness
Study NCT04502589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram will be kept at 250mg daily
Study NCT01471236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agili-C Bi-phasic Implant
Description: The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner.
Study NCT01471236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-arthrotomy
Description: The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded.
Study NCT01804283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic postconditioning
Description: multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest.
Study NCT01804283 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: double valve replacement
Description: The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
Study NCT01804283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double valve replacement
Description: The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
Study NCT01804283 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: heart-lung machine
Description: The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl cysteine, 1200mg (high dose)
Description: N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
Study NCT01251315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FT061452, 6000mg high dose
Description: Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
Study NCT04402385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants randomized to 81 mg of Aspirin daily
Study NCT00062985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail-based weight loss intervention
Study NCT00062985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based weight loss intervention
Study NCT01329900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
Study NCT01329900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
Study NCT04402385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo daily
Study NCT04692896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: different concentrations of lidocaine with same concentration of adrenaline
Study NCT01804283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart-lung machine
Description: The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
Study NCT01804283 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aortic cross-clamp
Description: a surgical instrument used in cardiac surgery to clamp the aorta
Study NCT01804283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic cross-clamp
Description: a surgical instrument used in cardiac surgery to clamp the aorta
Study NCT01606436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.
Study NCT04249284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT04249284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 prototype 1
Description: Specified dose on specified days
Study NCT04249284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 prototype 2
Description: Specified dose on specified days
Study NCT03822780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquin
Description: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
Study NCT01017666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014
Description: BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
Study NCT01017666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
Study NCT02170558 — intervention group
Intervention type: DEVICE
Intervention: TM- Ardis implant and Metal Reduction CT software
Description: TM- Ardis implant and Metal Reduction CT software
Study NCT01129414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01129414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral